Abstract: A compound for treating cancer tumors, particularly ovarian cancer tumors, is described, where a fused cyclic pyrimidine having a cancer treating ability is effective to allow selective delivery to a cancerous tumor.

Abstract: A method for treating cancer tumors, particularly ovarian cancer tumors, is described, where fused cyclic pyrimidine having a cancer treating ability is selectively delivered to an FR expressing cancerous tumor.

Abstract: Compositions for eliciting an immune response against Gram-negative bacterial infections and methods of making such compositions are provided. The composition comprises glycosylated pilin, the pilin being glycosylated with the O-antigen of a target Gram-negative bacteria of interest. Methods of eliciting an immune response by administration of such compositions are also provided.

Abstract: Compositions for eliciting an immune response against Gram-negative bacterial infections and methods of making such compositions are provided. The composition comprises glycosylated pilin, the pilin being glycosylated with the O-antigen of a target Gram-negative bacteria of interest. Methods of eliciting an immune response by administration of such compositions are also provided.

Abstract: A chemical imaging and process monitoring device which utilizes a computer controlled tunable laser to provide light at discrete wavelengths in the near infrared band and a focal plane array to image or a single-point photo detector to detect the intensity of light reflected from a sample illuminated at various wavelengths of light. The device also provides light intensity reference detectors at the source and terminus of the light delivery pathway for normalizing the collected data and for detecting defects in the light delivery pathway.

Abstract: A chemical imaging device which utilizes a computer controlled tunable laser to provide light of wavelengths in the near infrared band and a focal plane array to image a sample illuminated at various wavelengths of light. The device also provides light intensity reference detectors at the source and terminus of the light delivery pathway for normalizing the collected images and for detecting defects in the light delivery pathway.

Abstract: This invention discloses pyrimidine derivatives, and pharmaceutically acceptable salts and prodrugs thereof, useful in therapeutically and/or prophylactically treating patients with an illness. Such illnesses include cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. The compounds themselves, methods of making these compounds, and methods of using these compounds are all disclosed.

Abstract: A method of speciated isotope dilution mass spectrometry (SIDMS) which will permit determination of concentrations of one or more species from a sample even if the sample has been subjected to species conversion prior to species separation or degradation or incomplete separation exists. At least one predetermined stable isotope is spiked to convert the stable isotope to a speciated enriched isotope corresponding to the specie or species to be measured in the sample. The sample containing the species to be measured is spiked and the isotopic spiked specie and species to be measured are equilibrated. The species are separated from the sample and an isotope ratio determination for each specie to be measured is made. The species concentrations are then mathematically deconvoluted while correcting for species conversion and/or incomplete separation. The method may be employed to validate other methods. The method may also be employed in the preparation and analysis of speciated standard reference materials.

Abstract: This invention discloses pyrrolo pyrimidine compounds, and pharmaceutically acceptable salts, solvates and prodrugs thereof, of the following formula (3): These compounds are useful in therapeutically and/or prophylactically treating patients with cancer by inhibiting receptor tyrosine kinases and/or dihydrofolate reductase and/or thymidylate synthase. Methods of using these compounds, are also disclosed.

Abstract: Novel sulfatase inhibitor/estrogen receptor blocker compounds useful in the treatment of estrogen dependent illnesses are disclosed. The compounds generally comprise a sulfamate moiety and an aromatic, estrogen receptor blocker moiety. Methods for synthesizing these compounds and using them in the therapeutic and/or prophylactic treatment of an estrogen-dependent disease are also disclosed.

Abstract: This invention discloses compounds, and pharmaceutically acceptable salts thereof, useful in therapeutically and/or prophylactically treating patients with an illness. Such illnesses include cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. The compounds themselves, methods of making these compounds, and methods of using these compounds are all disclosed.

Abstract: Estra-1,3,5(10),16-tetraene derivatives represented by the following formula (I): (wherein R1 is as defined by the present specification.

Abstract: The present invention provides a controlled release pharmaceutical composition comprising a polydextrose, a drug that is complexed with the polydextrose, and a polymer matrix having the drug complexed with the polydextrose, wherein the polymer matrix and the polydextrose provide for a time release of the drug. A method of therapeutically treating a patient for an illness employing the controlled release pharmaceutical composition is also provided.

Abstract: The present invention provides a controlled release pharmaceutical composition comprising a polydextrose, a drug that is complexed with the polydextrose, and a polymer matrix having the drug complexed with the polydextrose, wherein the polymer matrix and the polydextrose provide for a time release of the drug. A method of therapeutically treating a patient for an illness employing the controlled release pharmaceutical composition is also provided.

Abstract: This invention discloses pyrimidine derivatives, and pharmaceutically acceptable salts and prodrugs thereof, of the following formula: wherein L and M are selected from the group consisting of carbon and CH, the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, wherein Z4 and Z5 are different and are selected from the group consisting of R14 and  where Z4 is R14 when Z5 is  and Z4 is  when Z5 is R14; wherein A1 is CH; wherein B1 is CH; wherein R17 is selected from the group consisting of aryl, diaryl, triaryl, mono-, di- or tri-substituted aryl, mono-, di- or tri-substituted diaryl, mono-, di- or tri- substituted triaryl, a substituted or unsubstituted heteroaryl and p-aroyl-L-glutamate; wherein R18 is a lower akyl group; and said compound capable of inhibiting dihydrofolate reductase and thymidylate synthase.

Abstract: Novel pyrrolo[3,2-d]pyrimidine derivatives of the following general formula are disclosed. These compounds are useful in the treatment of bacterial infections such as Toxoplasmosis gondii and Pneumocystis carinii, and various types of cancer, through their action on dihydrofolate reductase and thymidylate syndmase enzymes. Methods of inhibiting these enzymes, by administration of these compounds, are also disclosed.

Abstract: Novel sulfatase inhibitor compounds useful in the treatment of estrogen dependent illnesses are disclosed. These compounds generally comprise a steroid nucleus substituted at the C17 position. Methods for synthesizing these compounds and using them in the therapeutic and/or prophylactic treatment of a patient are also disclosed.

Abstract: Novel sulfatase inhibitor/estrogen receptor blocker compounds useful in the treatment of estrogen dependent illnesses are disclosed. The compounds generally comprise a sulfamate moiety and an aromatic, estrogen receptor blocker moiety. Methods for synthesizing these compounds and using them in the therapeutic and/or prophylactic treatment of an estrogen-dependent disease are also disclosed.

Abstract: This invention discloses compounds, and pharmaceutically acceptable salts, solvates and prodrugs thereof, useful in therapeutically and/or prophylactically treating patients with an illness. Such illnesses include cancer, and secondary infections caused by Pneumocystis carinii, Toxoplasma gondii, Mycobacterium tuberculosis, and Mycobacterium avium. The compounds themselves, methods of making these compounds, and methods of using these compounds are all disclosed. The compounds include 5-thiapyrimidines.

Abstract: This invention discloses compounds, and pharmaceutically acceptable salts thereof, useful in therapeutically and/or prophylactically treating patients with an illness. Such illnesses include cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. The compounds themselves, methods of making these compounds, and methods of using these compounds are all disclosed.